Congratulations to #TBCPartner @AtalantaTx who just announced an oversubscribed Series B financing of $97 million! The funding will support the advancement of Atalanta's RNAi medicines for CNS diseases, including clinical development for its investigational therapies targeting KCNT1-related epilepsy and Huntington’s disease. Named after the Greek heroine Atalanta, the company was founded to promote RNA interference that could silence disease-causing genes. This Nobel prize-winning science offers an opportunity to regulate genes and stop disease at its source. We can't wait to see what the future holds for this motivated team.

An exciting milestone for #TBCPartner @Palleon_Pharma, who is is teaming up with @HenliusBiotech to evaluate Palleon’s E-602 + Henlius’ rituximab HANLIKANG in clinical studies for #LupusNephritis. This marks the first application of glyco-immunology in autoimmune diseases. Well done, team Palleon!

#TBCPartner @intelliatx presented the first disease progression data from its Phase 1 trial of nex-z in transthyretin amyloidosis, an underappreciated cause of heart failure in elderly patients, during a special scientific session in Chicago this weekend to celebrate the 100th anniversary of the American Heart Association (@American_Heart). The data showed that nex-z has real potential to halt or even reverse the course of disease. With Phase 3 trials underway, we look forward to learning more about what Intellia’s revolutionary #CRISPR therapies can do for patients.

Last week, TBC’ers volunteered at @communityserv, a Boston-based nonprofit that prepares nutritious meals for individuals and families facing critical and chronic illnesses. Giving back to our community is core to our mission at Ten Bridge, and partnering with Community Servings is always an inspiring experience. We were proud to support their commitment to providing nutritious, home-delivered meals to those in need. We’re already looking forward to our next visit!

Huge congratulations to #TBCPartner @VeronaPharma, whose outstanding achievements for patients with #COPD were recognized by the #FierceInnovationAwards! Verona’s recently approved drug for the maintenance treatment of COPD is the first inhaled product with a novel mechanism of action in more than 20 years and has the potential to redefine the treatment landscape.

Last week #TBCPartner @intelliatx unveiled Phase 2 data from their trial of NTLA-2002 targeting hereditary angioedema (HAE), a rare disease that causes swelling attacks in various parts of the body. Data supported a functional cure for HAE - just one dose led to deep reduction of swelling attacks in patients. Excited to see this real patient impact from Intellia and all that is to come for their #CRISPR medicines!

Congrats to #TBCPartners @C4Therapeutics, Parabilis Medicines and @Sarepta who were recipients of this year’s @BostInno Fire Awards, a recognition that is given to local companies that have achieved significant advancements over the last year – including raising funds, launching new products and supporting the local community and innovation ecosystem.

#TBCPartner Archon Biosciences is coming out of stealth with $20M in seed financing at an incredibly exciting time. As this year’s Nobel Prize in Chemistry highlights, advances in protein design have created myriad of possibilities for improving human health. Archon is taking one of the most direct routes of applying this new technology by using generative protein design to transform antibodies into more effective drugs. We’re thrilled for the Archon team and join them in celebrating this momentous occasion! Learn more about their science and team at

Congratulations to Li Peng, Chief Scientific Officer of #TBCPartner @Palleon_Pharma, who was named to the 2024 @PharmaVoice 100 list! Li is a trailblazer in the growing field of glyco-immunology, shaping Palleon's approach and increasing enthusiasm for others to learn more about the science behind it.

Today #TBCPartner @SeaportTx , a founded entity of fellow #TBCPartner @PureTechH has successfully closed a Series B financing of $225 million led by @generalatlantic to progress its clinical-stage pipeline of neuropsychiatric medicines. Seaport is focusing on programs for major depressive disorder, generalized anxiety and mood disorders, one of the most challenging therapeutic areas for drug development.

Congratulations to David Baker for winning the Nobel Prize in Chemistry and, in the words of the Royal Swedish Academy of Sciences, achieving the ���almost impossible feat of building entirely new kinds of proteins.” Engineering proteins with novel shapes and functions unlocks nearly endless possibilities to create more effective medicines, diagnostics, and sensors. At Ten Bridge, we’re thrilled to be working alongside a biotech co-founded by David, to help translate his science and create the next generation of computationally designed drugs.

Congratulations to #TBCPartner @CityTx_ who launched last week with a $135 million Series A to improve and expand the therapeutic reach of RNAi-based medicines!

We were thrilled to be joined by @endpts co-founder @AKAarsalan at our team offsite this week. Thank you, Arsalan, for sharing your valuable insights and perspectives with us on the growth of Endpoints and what's to come in the industry.

Congrats to #TBCPartner @PureTechH on the FDA approval of Cobenfy (formerly KarXT), originally invented by the team at PureTech! This drug marks the first new innovation for the treatment of #schizophrenia in over 50 years. Read more:

Sincerest congratulations to #TBCPartners @capstantx and @SeaportTx, who last night were named as two of this year’s #Endpoints11!

#TBCPartner @imvax_inc's CEO John Furey recently connected with @AliGormanTV to discuss what’s on the horizon for the company and the progress it is making in its ongoing Phase 2 clinical trail in glioblastoma. Check out the interview below to learn more about what Imvax is doing to progress a potential new treatment for this vastly underserved treatment population. @BiotechTVHQ

#TBCPartner AIRNA today announced the successful closing of an oversubscribed $60 million financing round, an important step forward for their work to advance a broad RNA editing pipeline, including their lead program for alpha-1 antitrypsin deficiency (AATD). Read more in today’s piece by @AlexWestchester at @GENbio:

Exciting news for #TBCPartner @SOTIO which recently announced its latest partnership, further expanding its next-generation antibody-drug conjugate pipeline for the treatment of solid tumors. This marks SOTIO’s fourth partnership for the development of ADCs – a highly specific and potent treatment class.

Last week, some members of our team volunteered with the @CharlesRiver Watershed Association to remove invasive water chestnuts from the Charles River here in Massachusetts. Water chestnuts are an invasive aquatic plant found in the Charles River. They are rosette shaped and fast growing, thus blocking out other life in the river. Thanks to the CRWAs efforts, they have removed over 100 tons of water chestnuts from the Charles. Our team helped remove another 106 baskets of water chestnuts. Well done team, and thank you to the CRWA for another amazing volunteer experience!

Earlier this year, we had the privilege of partnering with #TBCPartner Clasp Therapeutics to launch their company and announce their Series A. Clasp is developing off-the-shelf precision immuno-oncology therapeutics to target hard-to-treat tumors with absolute specificity. Their launch was incredibly impactful, receiving some great recognition across key media outlets. Some of the communications highlights included: - 19 feature stories - 37 total pieces of coverage - Gained 2,500 LinkedIn followers in the first 24 hours following launch Learn more about our collaboration with Clasp in our recent case study: